

## Regimen Reference Order – nivolumab desensitization

Desensitization protocol is prescribed in combination with a nivolumab protocol

ARIA: SUPP - [nivolumab q 14 d (desens)]

SUPP - [nivolumab q 21 d (desens)]

SUPP - [nivolumab q 28 d (desens)]

Planned Course: Refer to prescribed nivolumab-based protocol

Indication for Use: Eligible patients with previous hypersensitivity reactions to nivolumab

Alert: Desensitization protocol

***nivolumab:***

- *nivolumab is prepared in 3 separate bags with a total volume of 50 mL in BAG 1, 50 mL in BAG 2 and 100 mL in BAG 3*
- *IV tubing is primed with nivolumab*
- *nivolumab is administered slowly following specified rate increases. nivolumab infusion takes approximately 4.5 hours to complete*

CVAD: At Provider’s Discretion

**Blood work requirements:**

- ❖ *Refer to prescribed nivolumab-based protocol*

### SEQUENCE OF MEDICATION ADMINISTRATION

#### Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
<i>Refer to prescribed nivolumab-based protocol</i>		

#### Treatment Regimen – nivolumab desensitization

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
<b>Day 1</b>		
cetirizine	20 mg	Orally <b>1 hour</b> prior to nivolumab
acetaminophen	975 mg	Orally <b>1 hour</b> prior to nivolumab
montelukast	10 mg	Orally <b>1 hour</b> prior to nivolumab
acetylsalicylic acid	650 mg	Orally <b>1 hour</b> prior to nivolumab
hydrocortisone	100 mg	IV in normal saline 50 mL over 15 minutes <b>1 hour</b> prior to nivolumab <i>*Nursing Alert: nivolumab starts 1 hour after completion of hydrocortisone infusion</i>

Wait 1 hour after completion of IV pre-medication(s) before starting nivolumab		
nivolumab	0.5% of dose (BAG 1)	IV in normal saline 50 mL following the administration rates below: <b>Step 1:</b> 2 mL/hour for 15 minutes, then <b>Step 2:</b> 5 mL/hour for 15 minutes, then <b>Step 3:</b> 10 mL/hour for 15 minutes, then <b>Step 4:</b> 20 mL/hour for 15 minutes <b>Once step 4 is complete, discard remainder of bag and proceed immediately to BAG 2</b> Use 0.2 or 0.22 micron filter <i>*Alert: Pharmacy to ensure final volume in bag = 50 mL</i> <i>*Nursing Alert: IV tubing is primed with nivolumab</i>
	5% of dose (BAG 2)	IV in normal saline 50 mL following the administration rates below: <b>Step 5:</b> 5 mL/hour for 15 minutes, then <b>Step 6:</b> 10 mL/hour for 15 minutes, then <b>Step 7:</b> 20 mL/hour for 15 minutes, then <b>Step 8:</b> 40 mL/hour for 15 minutes <b>Once step 8 is complete, discard remainder of bag and proceed immediately to BAG 3</b> Use 0.2 or 0.22 micron filter <i>*Alert: Pharmacy to ensure final volume in bag = 50 mL</i> <i>*Nursing Alert: IV tubing is primed with nivolumab</i>
	98.2% of dose (BAG 3)	IV in normal saline 100 mL following the administration rates below: <b>Step 9:</b> 10 mL/hour for 15 minutes, then <b>Step 10:</b> 20 mL/hour for 15 minutes, then <b>Step 11:</b> 40 mL/hour for 15 minutes, then <b>Step 12:</b> 80 mL/hour until infusion is complete Use 0.2 or 0.22 micron filter <i>*Alert: Pharmacy to ensure final volume in bag = 100 mL</i> <i>*Nursing Alert: IV tubing is primed with nivolumab</i>
<b>Maximum nivolumab dose is 240 mg (every 14 days) OR 360 mg (every 21 days) OR 480 mg (every 28 days)</b>		

In the event of an infusion-related hypersensitivity reaction, refer to the ‘Hypersensitivity Reaction Standing Order’

## REQUIRED MONITORING

### All Cycles

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O<sub>2</sub> saturation) at baseline and as clinically indicated
- No observation period is required after nivolumab administration. Patient can be discharged from treatment room if stable whether they had a reaction or not
- Refer to the prescribed nivolumab-based protocol for additional monitoring

### Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
<i>Refer to prescribed nivolumab-based protocol</i>		

---

### DISCHARGE INSTRUCTIONS

---

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity occur after discharge
- Refer to the prescribed nivolumab-based protocol for additional instructions

---

### ADDITIONAL INFORMATION

---

- Oncologist must write first prescription of nivolumab desensitization protocol
- Once the patient requires nivolumab desensitization protocol, all subsequent nivolumab doses must be given using nivolumab desensitization protocol
- Refer to the prescribed nivolumab-based protocol for additional nivolumab information
- Support protocols are available under **nivolumab q14d**, **nivolumab q21d** and **nivolumab q28d** in the “Desensitization” folder